Advancing Risk-Based Approaches in Blood Pressure Management: Reflections on the 2025 AHA/ACC Statement

Figures

• 

  Figure 1.. Proportional distribution of risk-based treatment pathways in the United States adult population according to the American Heart Association/American College of Cardiology (AHA/ACC) 2025 risk-based guideline for treatment of hypertension. Comorb denotes major comorbidities including established cardiovascular disease, diabetes, or chronic kidney disease, and risk denotes predicted 10-year risk of cardiovascular diseases using the Predicting Risk of Cardiovascular Diseases Events model. Green color depicts those not recommended for pharmacological therapy, amber depicts those subject to formal or informal risk assessment, and red is those subject to pharmacological therapy. Link to interactive plot: https://miladnazarzadeh.github.io/AHA_2025-_risk_assessment_for_BP/Final.html. BP indicates blood pressure; HTN, hypertension; and Rx, antihypertensive medications/prescriptions.

• 

  Figure 2.. Number needed to treat (NNT) to prevent 1 cardiovascular event, by hypertension stage, predicted cardiovascular risk and amount of blood pressure (BP) lowering. Absolute benefits estimated by product of predicted cardiovascular risk and 1-RR: RR=0.90SBP_diff/5, where SBP_diff =regimen efficacy, based on 5 mm Hg systolic blood pressure (SBP) reduction conferring RR, 0.90 (BPLTTC 2021). CV indicates cardiovascular; and RR, relative risk.